Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.46 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036985 | 0.94 | TSHR (0.44) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL7939372 | 0.92 | TSHR (0.43) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL25802171 | 0.92 | TSHR (0.43) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL831512 | 0.86 | — | — | |
| SCHEMBL18906900 | 0.83 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL18906770 | 0.83 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL6463788 | 0.81 | TSHR (0.50) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL8941662 | 0.80 | TSHR (0.42) | TSHRCES2HSD17B10MGAMGAA | |
| SCHEMBL1059079 | 0.80 | CES2 (0.52) | TSHRCES2HSD17B10ALDH1A1RECQL | |
| SCHEMBL16147050 | 0.79 | ALDH1A1 (0.50) | TSHRCES2HSD17B10MGAMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296929-A1 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE | 2025-09-25 | — | — | US | disclosed |
| EP-4320117-A2 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | Baruch S. Blumberg Institute (US) | 2024-02-14 | — | — | EP | disclosed |
| CN-117279909-A | Novel liver selective polyadenylation polymerase inhibitors and methods of use thereof | 巴鲁克斯布伦博格研究所 | 2023-12-22 | — | — | CN | disclosed |
| WO-2023230249-A1 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2022216552-A2 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | BARUCH S. BLUMBERG INSTITUTE (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250296929-A1 | NOVEL HEPATOSELECTIVE POLYADENYLATING POLYMERASES INHIBITORS AND THEIR METHOD OF USE | RNASE1, PAPSS1, PABPC1 | TSHR 4253/4885CES2 1131/4885HSD17B10 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.